Status: Recruiting
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will be compared to patients treated treated with colistin alone or colistin combined with meropenem.
Participants needed: 734
Trial details
Phase: Phase 4Age: 16+Biological sex: AllType: InterventionalSponsor: Rambam Health Care CampusUpdated: Aug 1, 2025Locations: 3
Eligibility criteria
More than 72 hours of therapy with in-vitro coverage against the CRAB within 96... [+9]